Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Semaglutide is an anti-diabetic medication used for the treatment of type 2 diabetes, and an anti-obesity medication used for weight management. It can be administered by subcutaneous injection or taken orally. It is sold as a generic drug by several drug companies in the Indian and Canadian markets, and worldwide by its originator, Novo Nordisk, under the brand names Ozempic and Rybelsus for diabetes, and under the brand name Wegovy for weight management. Semaglutide is also used in metabolic-associated steatohepatitis (nonalcoholic steatohepatitis) and to reduce the risk of major adverse cardiovascular events.
Read the full article on WikipediaDiabetes mellitus type 2 Clinical criteria: Treatment Phase: First PBS-prescription for this drug The treatment must be used in combination with at least one of: metformin, a sulfonylurea, insulin, AND The condition must be inadequately responsive to at least one of: metformin, a sulfonylurea, insulin, AND Patient must not have achieved a clinically meaningful glycaemic response with an SGLT2 inhibitor; OR Patient must have a contraindication/intolerance requiring treatment discontinuation of an SGLT2 inhibitor. Treatment criteria: Patient must not be undergoing concomitant PBS-subsidised treatment for type 2 diabetes mellitus with any of: an SGLT2 inhibitor, a DPP4 inhibitor, another GLP-1 receptor agonist.
“Semaglutide is a glucagon-like peptide-1 receptor agonist. The drug decreases blood sugar levels. The decrease is theorized to be caused by the mimicking of glucagon-like peptide-1 (GLP-1), an incretin. It also appears to enhance growth of pancreatic beta cells, which are responsible for insulin production and release.”
“7 days”
Working under the parallel aged-care framework? Aged-care equivalent →